Anavex Life Sciences Corp (AVXL)

[NWDR]

If the Rett trials confirm and improve (higher dose, younger patients) the first trial results then I firmly believe A2-73 will be approved for Rett treatment. If this happens then the market will begin to price in the other rare disease treatment approvals (highlighted in light blue). Not the full value but some percentage of possible approval which will increase as more trial data is completed, scrubbed and released.




The shares outstanding, percentage of patients treated, revenue per patient per year are all conservative.